HLN trades 13.8% below Wall Street's consensus target of $10.20.
Last 12 months price action with 12-month analyst target path
The base valuation assumes HLN achieves its forward estimates and maintains a stable P/E multiple of 21.3x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Haleon plc (HLN) has a Wall Street consensus price target of $10.20, based on estimates from 4 covering analysts. With the stock currently trading at $8.96, this represents a potential upside of +13.8%. The company has a market capitalization of $39.90B.
Analyst price targets range from a low of $10.20 to a high of $10.20, representing a 0% spread in expectations. The median target of $10.20 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, HLN trades at a trailing P/E of 18.7x and forward P/E of 21.3x. The forward PEG ratio of 2.52 reflects a premium valuation. Analysts expect EPS to grow -40.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $12.37, with bear and bull scenarios of $7.80 and $16.30 respectively. Model confidence stands at 37/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
KVUEKenvue Inc. | $34.8B | $18.12 | $18.25 | +0.7% | Hold | 15.2x | 14 |
CHDChurch & Dwight Co., Inc. | $22.7B | $95.64 | $105.00 | +9.8% | Buy | 25.5x | 34 |
PGThe Procter & Gamble Company | $351.4B | $150.38 | $159.00 | +5.7% | Buy | 21.8x | 52 |
CLColgate-Palmolive Company | $71.8B | $89.48 | $96.00 | +7.3% | Hold | 23.5x | 45 |
PBHPrestige Consumer Healthcare Inc. | $2.2B | $46.97 | $66.00 | +40.5% | Buy | 10.4x | 17 |
JNJJohnson & Johnson | $550.4B | $228.39 | $251.55 | +10.1% | Buy | 19.7x | 40 |
NVSNovartis AG | $280.6B | $147.08 | $170.00 | +15.6% | Hold | 16.9x | 25 |
GSKGSK plc | $101.9B | $50.67 | $52.45 | +3.5% | Hold | 14.0x | 29 |
MCKMcKesson Corporation | $90.2B | $750.63 | $994.86 | +32.5% | Buy | 17.0x | 31 |
CAHCardinal Health, Inc. | $52.2B | $221.77 | $253.38 | +14.3% | Buy | 20.6x | 33 |
Quick answers to the most common questions about buying HLN stock.
Haleon plc (HLN) has a consensus 12-month price target of $10.2, implying 13.8% upside from $8.96. The 4 analysts covering HLN see moderate appreciation potential.
HLN has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $10.2 implies 13.8% upside from current levels.
HLN trades at a forward P/E of 21.2675x, representing a moderate valuation. With analysts targeting $10.2 (13.8% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $10.2 for HLN, while the most conservative target is $10.2. The consensus of $10.2 represents the median expectation. Our quantitative valuation model projects a bull case target of $16 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
HLN is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HLN stock forecast based on 4 Wall Street analysts shows a consensus price target of $10.2, with estimates ranging from $10.2 (bear case) to $10.2 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $12, with bear/bull scenarios of $8/$16.
Our quantitative valuation model calculates HLN's fair value at $12 (base case), with a bear case of $8 and bull case of $16. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 37/100.
HLN trades at a forward P/E ratio of 21.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 18.7x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on HLN, with a "Buy" consensus rating and $10.2 price target (13.8% upside). 3 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HLN analyst price targets range from $10.2 to $10.2, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10.2 consensus represents the middle ground. Our model's $8-$16 range provides an independent fundamental perspective.
Deep dive into HLN consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.